7/27/2019 Neuroendocr Lecture
1/64
7/27/2019 Neuroendocr Lecture
2/64
GASTROENTEROPANCREATICNEUROENDOCRINE TUMOURS
PROF DR : ABDEL RAHMAN A MOKHTARInternal Medicine Mansoura University
7/27/2019 Neuroendocr Lecture
3/64
DEFINITION AND CHARACTERS:
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are considered to berare, heterogeneous and complex neoplasms.
They include the pancreatic (PNETs) and gastrointestinal (GI) neuroendocrinetumours (GI-NETs) or carcinoids, which share their origin of cells from the diffuseneuroendocrine system , but further show many differences regarding
pathogenesis, clinical behaviour and prognostic outcome.Characteristic for GEP-NETs is their ability to produce bioactive substances
Based on the clinical symptoms and syndrome caused by these peptides, theycan be divided into functioning (F-NETs) and non-functioning tumours (NF-NETs).
Although GEP-NETs are generally more indolent than carcinomas, the majority aremalignant, showing aggressive tumour behaviour and presenting with metastasesat diagnosis.
GEP-NETs can occur sporadically, or as part of a hereditary syndrome such asmultiple endocrine neoplasia syndrome type 1 (MEN-1), von-Hippel Lindau
disease (vHLD), neurofibromatosis type 1, or tuberous sclerosis.
7/27/2019 Neuroendocr Lecture
4/64
GEP-NETs arise from cells of the diffuse neuroendocrine system (DNES) and untilrecently were believed to derive from migrated neural crest cells.
In fact, they actually derive from local multipotent GI stem cells, rather than
by migration of the neural crest cells, and hence are endodermal in originThe gut DNES cells are remarkably heterogeneous and consistof 14 different types of cells making it the largest endocrine organ inthe body.
The secretion of bioactive amines is regulated by mechanical and chemicalstimuli. Adenyl cyclase,b-adrenoceptors, and pituitary adenylate cyclase activating
polypeptide are activating pathwaysWhereasSomatostatin (via somatostatin receptor 2),acetylcholine (muscarinic
acetylcholine receptor M4), and c-aminobutyric acid (GABA) (via GABA-Areceptors) are inhibitory signals.It is the secretion of these bioactive amines that make these tumors unique
in their biological characteristics
7/27/2019 Neuroendocr Lecture
5/64
NOMENCLATURE ISSUES
Endocrine versus neuroendocrineOriginally, the concept of neuroendocrine neoplasia reflected the hypothesis thatthe cells from which these tumors were derived originated from the embryonicneural crest. This concept was disproved years ago, causing some authorities toadvocate abandoning the term neuroendocrine in favor of endocrine.
However, the neoplastic cells also possess features of neural and epithelialcells, and for this reason, the most recent edition of the WHOclassification of tumors of the digestive system has once againrecommended the use of neuroendocrine
Tumor instead of neoplasmCertainly, all of the entities under discussion are neoplastic, and neoplasm istherefore a more accurate term than tumor, which means onlya mass. However, neuroendocrine tumor (NET) has achieved widespreadacceptance in many systems and will be used here in stead of the more correct
but less accepted alternative, neuroendocrine neoplasm.
7/27/2019 Neuroendocr Lecture
6/64
Carcinoid tumor (from the German karzinoide or cancer -like)
In 1907, Oberndorfer introduced this term for neuroendocrine tumours with arelatively benign course.Increasing knowledge about these tumours, however, led to the conclusion thatcarcinoids also encompass low-grade and high-grade malignant tumours.
Therefore, Soga et al. called the term carcinoid a misnomer
In fact, this term has been used for different goals;whereas pathologists label all tumours with neuroendocrine features as
a carcinoid, clinicians use carcinoid for serotonin -producing tumoursthat lead to the carcinoid syndrome.
7/27/2019 Neuroendocr Lecture
7/64
Therefore, Capella et al.suggested replacing carcinoid by neuroendocrine tumour to include all tumours withneuroendocrine features, but also realised that abandoning this term completely wouldbe too confusing, and therefore proposed to utilise it for the specification of a NET with serotonin production or producing any other substance
which may lead to the carcinoid syndrome.
Hence, the current nomenclature systems such as the European NeuroendocrineTumor Society(ENETS) and the World Health Organization (WHO) embrace the
term GEP -NETs for tumors of epithelial origin occurring in thegastrointestinal (GI) tract with neuroendocrine differentiation.
7/27/2019 Neuroendocr Lecture
8/64
CLASSIFICATION :
7/27/2019 Neuroendocr Lecture
9/64
GI NEUROENDOCRINE
TUMORSPancreatic NETs Insulinoma Glucagonoma VIPoma Pancreatic
polypeptidoma
Foregut Thymus Esophagus Lung
Stomach Duodenum
Midgut Appendix Ileum Cecum Ascending
colon
Hindgut Distal largebowel
Rectum
Other NETS
7/27/2019 Neuroendocr Lecture
10/64
Differentiation and Grading ISSUES
Differentiation
refers to the extent thatneoplastic cells resemble their non-neoplastic counterparts
GRADE : refers tothe inherent biologic
aggressiveness of thetumor
7/27/2019 Neuroendocr Lecture
11/64
7/27/2019 Neuroendocr Lecture
12/64
1 9 7 3
1 9 7 4
1 9 7 5
1 9 7 6
1 9 7 7
1 9 7 8
1 9 7 9
1 9 8 0
1 9 8 1
1 9 8 2
1 9 8 3
1 9 8 4
1 9 8 5
1 9 8 6
1 9 8 7
1 9 8 8
1 9 8 9
1 9 9 0
1 9 9 1
1 9 9 2
1 9 9 3
1 9 9 4
1 9 9 5
1 9 9 6
1 9 9 7
1 9 9 8
1 9 9 9
2 0 0 0
2 0 0 1
2 0 0 2
2 0 0 3
2 0 0 4
0.00
1.00
2.00
3.00
4.00
5.00
6.00
0
100
200
300
400
500
600
I n c i d e n c e p e r 1 0 0 , 0 0 0 -
N E T s
I n c i
d e n c e p e r 1 0 0
, 0 0 0
A l l m
a l i g n a n t n e o p
l a s m s
All malignant neoplasms
Neuroendocrine tumors
Yao JC et al. J Clin Oncol . 2008;26:3063-3072.
INCIDENCE OF NETS INCREASING
7/27/2019 Neuroendocr Lecture
13/64
INCREASING INCIDENCES OF NET
Increased incidence of carcinoid tumours, US population 1973 2005Overall increase recorded for all primary sites during this period. Data from SEER
database, US National Cancer InstituteModlin et al. Lancet Oncol 2008; 9: 61 72
7/27/2019 Neuroendocr Lecture
14/64
NETS ARE THE SECOND MOST PREVALENTTYPE OF GI MALIGNANCY
2x more prevalent
than pancreatic cancer
]
1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2004. http://seer.cancer.gov/csr/1975_2004. 2. Modlin IM, Lye KD, Kidd M.Cancer . 2003;97(4):934-959.
]
7/27/2019 Neuroendocr Lecture
15/64
7/27/2019 Neuroendocr Lecture
16/64
7/27/2019 Neuroendocr Lecture
17/64
EPIDEMIOLOGIC NOTES FOR THE CLINICIAN
1) It is imp ortant to real ise that GEP-NETs frequent ly oc cur as or together wi th a second pr imary m al ignancy.The presence of a simultaneous second primary or metastatic malignancy must bethoroughly examined, as several case reports describe the existence of a second tumour synchronous with a carcinoid lesion.
For example, gastrointestinal stromal tumours (GIST) are frequently seen in combinatiowith (gastric) carcinoids.
Therefore, alertness for synchronous (neuroendocrine) tumours among clinicians isadvocated.
2) Pat ients su ffer ing fro m heredi tary s yn drom es suc h as MEN-1, vHLD,neurof ibro m atosis type 1 or tub erous sc lerosis , are a t increased r isk fo r a GEP-NET . So, members from hereditary GEP-NET disorder familiesshould be checked for such tumours, preferably by genetic counselling and, if possible,DNA profile, or by measurement of markers for these or associated tumours.
7/27/2019 Neuroendocr Lecture
18/64
3) A no ther d iff icul ty in d iagn os ing GEP-NETs ar ises as these tumours show a relatively high frequency of ectopic occurrence.
For example, gastrinomas, which are usually located in the pancreaticoduodenalregion and lymphnodes, have been reported on ectopic locations suchas ovaries, biliary tract, kidneys, stomach and liver.
Some authors believe that it is uncertain whether these ectopic locations compriseprimary gastrinomas rather than metastases of occult primaries.
GEP-NETs have been reported in rare locations such as the oesophagus, gallbladder and biliary ducts, Meckels diverticulum, ampulla of Vater, genital tract and skin.
Lack of awareness that neuroendocrine lesions can also occur on these unusual sitesresults in the consequence that these tumours are frequently misdiagnosed or
overlooked.
Therefore, it is recommended that when imaging is not successful in detecting aneuroendocrine tumour in the usual sites, an intensive search for occult tumours atunusual sites should be started.
Additionally, it is important to realise that
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
19/64
PRESENTATIONASYMPTOMATIC . VAGUE SYMPTOMS,CARCINOID SYNDROME.GASTROINTESTINAL NET.PANCREATIC NET..FUNCTIONING & NONFUNCTIONING.BRONCHIAL NET.METASTATIC DISEASE.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
20/64
7/27/2019 Neuroendocr Lecture
21/64
NONSPECIFIC SYMPTOMS OFTEN LEAD TO A DELAYED DIAGNOSIS
1. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. J Natl Cancer Inst . 2008;100(18):1282-1289.
Presents toprimary care
Vague abdominal
symptoms
May be diagnosedas IBS
May be referredto specialists for evaluation whensymptoms donot resolve
Referred tomultiplespecialists
Symptomsbecome worseor patient
consultsfor another reason
Diagnosisremains unclear
Seen bygastroenterologistor other specialistwho orders imaging
A referral leadsto a scan or patient
scanned for another reason
Liver metastasis or primary lesion isvisualized
May be anincidental finding
Surgeon,pathologistperform biopsyor resection
Biopsy provides diagnosis of NET
Patient is referred tosurgical oncologist,medical oncologist,or endocrinologist
Treatment dependson stage, histology,symptoms
Estimated time to diagnosis: 5 to 7 years 1
7/27/2019 Neuroendocr Lecture
22/64
Vague abdominalsymptoms
Primary tumor
Flushing
Metastases
Diarrhea
Death
NETS ARE OFTEN DIAGNOSED LATE
Time
Vinik A, Moattari AR. Dig Dis Sci . 1989;34[Suppl]:14S-27S.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
23/64
PRESENTATIONASYMPTOMATIC . VAGUE SYMPTOMS,CARCINOID SYNDROME.GASTROINTESTINAL NET.PANCREATIC NET..FUNCTIONING & NONFUNCTIONING.BRONCHIAL NET.METASTATIC DISEASE.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
24/64
7/27/2019 Neuroendocr Lecture
25/64
CARCINOID SYNDROME About 50% of patients with carcinoid
syndrome have cardiacabnormalities caused by chronicexposure of the heart valves toserotonin, which causes fibrosisand thickening of the tricuspid andpulmonary valves, resulting in
regurgitation or, less commonly,stenosis.
Right heart failure andcongestive cardiac failure can result.
.Ascites and oedemacan also occur. The consequenthepatic congestion results in adecreased capacity of the liver todegrade hormones, which further exacerbates symptoms and can result
in acute decompensation.
7/27/2019 Neuroendocr Lecture
26/64
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
27/64
PRESENTATIONASYMPTOMATIC . VAGUE SYMPTOMS,CARCINOID SYNDROME.GASTROINTESTINAL NET.PANCREATIC NET..FUNCTIONING & NONFUNCTIONING.BRONCHIAL NET.METASTATIC DISEASE.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
28/64
Gastrointestinal NETs
Small-bowel carcinoids are frequently asymptomatic or present with vagueabdominal symptoms that can be mistaken for irritable bowel syndrome.
Some patients present with intermittent or acute bowel obstruction.Production of serotonin or other bioactive amines is a typical
feature of small-bowel carcinoids, and local secretion causes mesentericfibrosis that predisposes to bowel obstruction or can compress mesenteric vessels,resulting in bowel ischaemia and malabsorption.
Most gastric, appendiceal and rectal carcinoids present as incidentalfindings.
These tumours are usually non-functioning and remain asymptomatic untiladvanced.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
29/64
PRESENTATIONASYMPTOMATIC . VAGUE SYMPTOMS,CARCINOID SYNDROME.GASTROINTESTINAL NET.PANCREATIC NET..FUNCTIONING & NONFUNCTIONING.BRONCHIAL NET.METASTATIC DISEASE.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
30/64
Pancreatic NETsNon-functioning pancreatic NETsmay grow for a long time withoutcausing symptoms.When large enough, obstruction of bile or pancreatic
ducts may causeobstructive jaundice or symptoms due to pancreatic enzyme insufficiency, such
as diarrhoea.
About half of pancreatic NETs are functional producing a
7/27/2019 Neuroendocr Lecture
31/64
About half of pancreatic NETs are functional , producing arange of hormones resulting in characteristic syndromes .
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
32/64
PRESENTATIONASYMPTOMATIC . VAGUE SYMPTOMS,CARCINOID SYNDROME.GASTROINTESTINAL NET.PANCREATIC NET..FUNCTIONING & NONFUNCTIONING.BRONCHIAL NET.METASTATIC DISEASE.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
33/64
Bronchial NETsBronchial carcinoid tumours can cause
Recurrent pneumonia from airway obstruction,Pleurisy, haemoptysis and shortness of breath.
A small proportion of these tumours produce serotonin or similar bioactive hormones, resulting in carcinoid syndrome, or ACTH,
resulting in Cushings syndrome.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
34/64
PRESENTATIONASYMPTOMATIC . VAGUE SYMPTOMS,CARCINOID SYNDROME.GASTROINTESTINAL NET.PANCREATIC NET..FUNCTIONING & NONFUNCTIONING.BRONCHIAL NET.METASTATIC DISEASE.
http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=1371931130058328http://www.google.com.eg/url?sa=i&rct=j&q=Logo%20for%20presentation&source=images&cd=&cad=rja&docid=xTAPYxGHGKDCdM&tbnid=0j8CihJOL9nsIM:&ved=0CAUQjRw&url=http%3A%2F%2Fwww.logodesignconsultant.com%2Flogo_article%2FLogo-creation.html&ei=jrDEUeflDszJswabqIGwCA&psig=AFQjCNFk8z0w9zs9mrPCCxvDD0b3i3vkmg&ust=13719311300583287/27/2019 Neuroendocr Lecture
35/64
Metastatic diseaseCommon sites of metastatic diseaseinclude :- Local or distant lymph nodes,-Liver, bone and peritoneum.-In females the ovary can be a site of metastatic disease.
Some patients present with symptoms of fatigue and weight loss.
Unlike other malignancies in which untreated metastatic disease is usuallyrapidly progressive, even widely spread metastatic NETs can be indolent,sometimes referred to as cancer in slow motion.
It is not uncommon for it to present initially as a cancer of
unknown primary, as the burden of metastatic disease can be large, whilethe primary site remains small and difficult to locate.
7/27/2019 Neuroendocr Lecture
36/64
INVESTIGATION
CgA is an acidic glycoprotein
http://www.google.com.eg/url?sa=i&source=images&cd=&cad=rja&docid=cdCZDEJZ-MRTQM&tbnid=N8JyKJIDp0JxqM:&ved=0CAgQjRwwAA&url=http%3A%2F%2Fvox.publika.md%2Fpolitica%2Fin-apararea-lui-zubco-e-necesara-o-ancheta-internationala-382441.html&ei=R8nEUebKLZDDswajpIH4Cg&psig=AFQjCNFgEWTUkP1tlJQIQJJwCBRIb4cJyw&ust=13719374797846807/27/2019 Neuroendocr Lecture
37/64
CgA is an acidic glycoproteinexpressed in the secretory granulesof most normal and neoplasticneuroendocrine cell types.
7/27/2019 Neuroendocr Lecture
38/64
CHROMOGRANIN A (CGA): A VALUABLE DIAGNOSTICAND PROGNOSTIC TOOL
Highly elevated serum CgA and/or immunohistochemical (IHC) staining of tumor for CgA is diagnostic of NETs
Offers 85% sensitivity and 96% specificity for NETs1
CgA can be used to monitor treatmentresponse
More sensitive than radiology for measuringprogression 2
References: 1. Campana D, Nori F, Piscitelli L, et al. J Clin Oncol . 2007;25(15):1967-1973. 2. Eriksson B, berg K, Stridsberg M. Digestion . 2000;62(suppl 1):33-38.
7/27/2019 Neuroendocr Lecture
39/64
CHALLENGES PRESENT WITH CGA TESTING
Other conditions can cause elevated CgARisk of false positivesSevere hypertensionGastric acid suppression (PPIs) Renal insufficiencyChronic atrophic gastritis.
CgA values vary considerablyBetween different types of NET
Test kits not universally standardizedDifferent standards, units of measuresDifferent antibodiesDifferent detection system
7/27/2019 Neuroendocr Lecture
40/64
IF SUSPICION OF ASPECIFIC SYND ,TESTS FORHORMONEEXCESSES AREINDICATED
5 HIAA (24 HR URINE COLLECTION)
7/27/2019 Neuroendocr Lecture
41/64
5 HIAA (24-HR URINE COLLECTION)SEROTONIN (BLOOD, MORE VARIABLE)
5-HIAA = 5-hydroxyindoleacetic acid
5-Hydroxyindole acetic acid (5-HIAA) is the urinary breakdownproduct of serotonin and can be measured using a 24-hour urinecollection in patients with features of carcinoid syndrome.
Some foods, including pineapples, bananas, eggplants, tomatoes,avocados and walnuts contain high levels of serotonin, which can
increase urinary levels of 5-HIAA, and should be avoided three daysbefore collection.
5-HIAA can also be increased in patients with untreatedmalabsorption such as in coeliac disease.
A variety of medications can also increase or decrease 5-HIAAlevels.CgA measurement is more sensitive and is increasingly replacing use of urinary 5-HIAA
7/27/2019 Neuroendocr Lecture
42/64
OTHER MARKERS IN FUNCTIONAL TUMORS
Gastrinoma
Gastrin
Glucagonoma
Glucagon
Insulinoma
Insulin
Pro-insulin
C-peptide
VIPoma
Vasoactiveintestinalpeptide
Fasting measurements when possible
7/27/2019 Neuroendocr Lecture
43/64
7/27/2019 Neuroendocr Lecture
44/64
7/27/2019 Neuroendocr Lecture
45/64
EchocardiographyCarcinoid heart disease is seen in a high proportion of patients withlongstanding carcinoid syndrome,and echocardiography is needed to assess this.
Specific features are thickening of valvular cusps and chordae, whichresults in regurgitation or stenosis (usually of the tricuspid valve) leadingto right ventricular dilation and reduced function, as well as right atrialdilation
7/27/2019 Neuroendocr Lecture
46/64
DIAGNOSTIC
ALGORITHM
7/27/2019 Neuroendocr Lecture
47/64
DIAGNOSTICALGORITHM
7/27/2019 Neuroendocr Lecture
48/64
DIAGNOSTICALGORITHM
7/27/2019 Neuroendocr Lecture
49/64
TREATMENTGiven the complexity and heterogeneity of this disease, therapy isindividualised based on several factors, including:
Disease extent.
Rate of growth determined by temporal change on imaging and histological
grade/proliferative index. Level of SSTR expression .
Disease -related symptoms with regard to the primary lesion or metastatic deposits.
Patient comorbidities.
7/27/2019 Neuroendocr Lecture
50/64
TREATMENT OPTIONS
Surgery (curative vs debulking)Radiofrequency ablationChemo-embolizationSomatostatin analogue (hormonal treatment)Chemotherapy or other medical therapy(targeted kinase inhibitors)Biologic therapy.Radionuclide therapy
7/27/2019 Neuroendocr Lecture
51/64
The two current ly avai lable
7/27/2019 Neuroendocr Lecture
52/64
SSAs are oc treot ide (Sandostatin100- 500 g [a short-acting preparation]
and Sandostatin LAR 10-30mg [a long-acting repeatabledepot preparation]) and lanreotide(Lanreotide Autogel 60,90, 120mg [a depot preparation]).The short-acting is SChas a half-life of 1.5-2 hours andis used for the treatment of breakthroughsecretory symptoms.
The depot preparations are given once every four weeks by deep SC or IM injections and are used for long-term control.These agents do have adverseeffects, including: Nausea. Cramping. Diarrhoea. Steatorrhoea. Cardiac conduction abnormalities. Endocrine dysfunction hpothyroidism,hypo- and hyperglycaemia).
Cholelithiasis in up to 50% of patients (although cholecystitisdevelops in fewer than 5%).Patients undergoing surgicalresection of NETs should beconsidered for prophylactic
cholecystectomy to facilitatelater use of SSAs.
7/27/2019 Neuroendocr Lecture
53/64
RADIOFREQUENCY ABLATION
7/27/2019 Neuroendocr Lecture
54/64
CHEMOEMBOLISATION
7/27/2019 Neuroendocr Lecture
55/64
CHEMOEMBOLISATION
7/27/2019 Neuroendocr Lecture
56/64
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY The use of beta particle emitters ,Indium111,Y-90 and lutetium-177 (Lu-177).
The last 2 in the form of Y-90 andLu-177 DOTATATE (LuTate) arenow preferred and havedemonstrated excellent objectiveresponse rates(about 70%) with low toxicity.High-energy beta particles fromY- 90 can travel up to a centimetrein tissue whereas lower-energy
particles from Lu-177 travel1-2mm.Both result in crossfire, whereby each cell irradiates its neighbours,resulting in efficient radiationdelivery to aggregations of cancer cells.
7/27/2019 Neuroendocr Lecture
57/64
7/27/2019 Neuroendocr Lecture
58/64
Q i
7/27/2019 Neuroendocr Lecture
59/64
Quiz
7/27/2019 Neuroendocr Lecture
60/64
QUIZ
7/27/2019 Neuroendocr Lecture
61/64
QUIZ
7/27/2019 Neuroendocr Lecture
62/64
QUIZ
7/27/2019 Neuroendocr Lecture
63/64
QUIZ
7/27/2019 Neuroendocr Lecture
64/64
THANK YOU